Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
guiding 2026 revenue to $435M–$450M while noting low penetration (~30% idiopathic, Feb 2035) with one litigant (Hetero) still pending. Agamree has shown strong early commercial traction after its March 2024 launch (68% Q4 growth), with high payer coverage and adoption in top DMD centers, and supportive GUARDIAN data increasing confidence in the ongoing SUMMIT trial and management's $140M–$150M 2026 revenue target for the product. Fycompa has faced expected generic erosion (2026 guidance $40M–$45M vs prior ~$115M) while Catalyst sits on $700M cash with no funded debt, a $200M share-repurchase authorization, and a stated priority to deploy capital into rare-disease acquisitions (including near-market/Phase 3 assets) and selective M&A. Interested in Catalyst Pharmaceuticals, Inc.? Here are five stocks we like better. 2 Biotechs Making Waves With A Single Product in their Pipeline Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio a
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness [Yahoo! Finance]Yahoo! Finance
- Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? [Yahoo! Finance]Yahoo! Finance
- Full Year 2025 Trading Update [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount [Yahoo! Finance]Yahoo! Finance
CPRX
Earnings
- 2/25/26 - Beat
CPRX
Sec Filings
- 3/19/26 - Form 8-K/A
- 3/18/26 - Form 8-K
- 2/25/26 - Form 8-K
- CPRX's page on the SEC website